Gylden Pharma
Clinical-stage biotechnology company developing intradermal delivery systems and synthetic T-cell‑priming vaccines. Maintains two core technology approaches — microneedle-based intradermal delivery and gold nanoparticle‑based peptide vaccine carriers — and supports discovery through clinical development, GMP manufacturing, regulatory interactions, and external research partnerships. Has completed venture financing to support pipeline progression and maintains collaborations for preclinical viral studies.
Industries
Nr. of Employees
small (1-50)
Gylden Pharma
Abingdon-On-Thames, England, United Kingdom
Patents
Products
Microneedle patch for systemic delivery of small molecules (migraine program)
Microneedle patch formulation designed to deliver small‑molecule therapeutics transdermally for rapid systemic uptake; programme has completed late‑stage clinical evaluation and has engaged in regulatory submission activities.
Gold nanoparticle‑based intradermal vaccine platform
Programmable nanoparticle carrier system with surface chemistries and synthetic peptide antigens for intradermal delivery to antigen‑presenting cells, developed for infectious disease and oncology T‑cell vaccine applications.
Microneedle patch for systemic delivery of small molecules (migraine program)
Microneedle patch formulation designed to deliver small‑molecule therapeutics transdermally for rapid systemic uptake; programme has completed late‑stage clinical evaluation and has engaged in regulatory submission activities.
Gold nanoparticle‑based intradermal vaccine platform
Programmable nanoparticle carrier system with surface chemistries and synthetic peptide antigens for intradermal delivery to antigen‑presenting cells, developed for infectious disease and oncology T‑cell vaccine applications.
Services
cGMP production of nanoparticle‑based vaccines and commercial microneedle patch manufacturing for clinical and commercial supply.
End‑to‑end preclinical development, toxicology testing and clinical trial execution support across early and late‑phase studies for intradermal vaccines and therapeutics.
Collaborative research, licensing of platform technologies and joint development agreements with academic, industry and government partners for vaccine and device projects.
Engagement of authenticated biological materials providers and contract partners to perform wild‑type viral infection models and MHC Class I peptide analyses to support epitope confirmation.
cGMP production of nanoparticle‑based vaccines and commercial microneedle patch manufacturing for clinical and commercial supply.
End‑to‑end preclinical development, toxicology testing and clinical trial execution support across early and late‑phase studies for intradermal vaccines and therapeutics.
Collaborative research, licensing of platform technologies and joint development agreements with academic, industry and government partners for vaccine and device projects.
Engagement of authenticated biological materials providers and contract partners to perform wild‑type viral infection models and MHC Class I peptide analyses to support epitope confirmation.
Expertise Areas
- Intradermal drug and vaccine delivery
- T‑cell priming vaccine development and epitope discovery
- Nanoparticle carrier design and scale‑up
- GMP vaccine manufacturing and process scale‑up
Key Technologies
- Microneedle intradermal delivery
- Gold nanoparticle vaccine carriers
- Synthetic peptide vaccine constructs
- Ligandome mapping / immunoproteomics
News & Updates
Raised over US$11 million in a Series A round to support clinical and preclinical progression of synthetic T‑cell vaccine programmes, with participation from venture investors.
Entered into an agreement with an authenticated biological materials and standards organisation to perform wild‑type viral infection models and immunoproteomics analyses for a Yellow Fever booster candidate (BSL‑3 work via partner).
Appointed a business development director and a manufacturing director to strengthen commercial and manufacturing capabilities supporting pipeline advancement and collaborations.
Commentary noting a peer‑reviewed paper that supports the role of T‑cell responses in SARS‑CoV‑2 clearance and long‑term immune memory, cited as supporting evidence for T‑cell vaccine approaches.
Regulatory approval for manufacturing and import authorisation (MIA/IMP) was obtained to support clinical manufacturing activities.
A T‑cell priming vaccine candidate for betacoronaviruses was selected for inclusion in NIH/NIAID Project NextGen clinical trials.
Raised over US$11 million in a Series A round to support clinical and preclinical progression of synthetic T‑cell vaccine programmes, with participation from venture investors.
Entered into an agreement with an authenticated biological materials and standards organisation to perform wild‑type viral infection models and immunoproteomics analyses for a Yellow Fever booster candidate (BSL‑3 work via partner).
Appointed a business development director and a manufacturing director to strengthen commercial and manufacturing capabilities supporting pipeline advancement and collaborations.
Commentary noting a peer‑reviewed paper that supports the role of T‑cell responses in SARS‑CoV‑2 clearance and long‑term immune memory, cited as supporting evidence for T‑cell vaccine approaches.
Regulatory approval for manufacturing and import authorisation (MIA/IMP) was obtained to support clinical manufacturing activities.
A T‑cell priming vaccine candidate for betacoronaviruses was selected for inclusion in NIH/NIAID Project NextGen clinical trials.